|
Is Traffic Getting Worse in Rancho Cucamonga? Residents Are Feeling the Impact of Growth David VanGorden, candidate for Rancho Cucamonga City Council District 2, discusses traffic congestion and infrastructure planning as the city continues to grow. He is running against incumbent Kristine Scott and candidate DeJonae Shaw. As Rancho Cucamonga continues to grow, residents … Continue reading
|
Can Rancho Cucamonga Infrastructure Keep Up With Growth? Residents Are Asking the Question David VanGorden, candidate for Rancho Cucamonga City Council District 2, discusses infrastructure and growth planning as Rancho Cucamonga continues to grow. He is running against incumbent Kristine Scott and candidate DeJonae Shaw. As Rancho Cucamonga continues to grow, residents are … Continue reading
|
|
The Chronic Inflammatory Demyelinating Polyneuropathy market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease awareness, improving diagnostic capabilities, and the anticipated launch of emerging therapies such as Riliprubart (Sanofi), Batoclimab (Immunovant), … Continue reading
|
The Pulmonary Arterial Hypertension market is expected to grow steadily across the 7MM, driven by increasing disease awareness, improving diagnostic capabilities, and the anticipated launch of emerging therapies such as ralinepag (United Therapeutics), PF-07868489 (Pfizer), RT234 (Respira Therapeutics), seralutinib (Gossamer … Continue reading
|
|
Minimal Residual Disease Clinical Trial Key Minimal Residual Disease companies such as Genentech, AmMax Bio, and Precigen Inc are at the forefront of Minimal Residual Disease innovation, leveraging cutting-edge platforms to develop therapies that target residual disease with high precision. … Continue reading
|
The Cervical Dystonia market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease awareness, improving diagnosis rates, and the anticipated launch of emerging therapies such as ABP-450 (AEON Biopharma) and IPN10200 (Ipsen), … Continue reading
|
|
Hearing Loss Clinical Trial Key Hearing Loss Companies include Sensorion, AudioCure Pharma GmbH, Acousia Therapeutics, Neuracle Science, Regeneron Pharmaceuticals, Sound Pharmaceuticals, PAEAN Biotechnology, and others The Hearing Loss therapeutic landscape is undergoing a significant transformation, driven by robust clinical innovation … Continue reading
|
Lipodystrophy Clinical Trial Emerging Lipodystrophy therapeutic approaches include leptin receptor agonists, apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) antagonists, and gene-based therapies. Lipodystrophy companies such as Regeneron Pharmaceuticals and other emerging biotech innovators are actively reshaping the therapeutic landscape through … Continue reading
|
|
Hypertriglyceridemia Pipeline Key Hypertriglyceridemia companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals are leveraging advanced technologies such as RNA interference and antisense platforms to develop highly targeted therapies. Hypertriglyceridemia companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer … Continue reading
|
Von Willebrand’s Disease Clinical Trial Key Von Willebrand’s Disease Companies include Star Therapeutics, Hemab, Vega Therapeutics, and others The Von Willebrand’s Disease (VWD) therapeutic landscape is entering a phase of strategic transformation, driven by increasing research investments, novel biologic approaches, … Continue reading
|
